ScreenerHero

BWAYBrainsWay Ltd.

NAS · US · Healthcare · Medical Devices · brainsway.com
14.74USDMkt Cap: 592.39M $P/E: 64.09

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the…

Industry Peers

Medical Devices
Screen all
ABT
Abbott Laboratories
$203.17BUSDP/E 37.7
SYK
Stryker Corporation
$126.37BUSDP/E 34.2
MDT
Medtronic plc
$119.49BUSDP/E 25.0
BSX
Boston Scientific Corporation
$73.00BUSDP/E 20.4
SHL
Siemens Healthineers AG
$48.43BUSDP/E 19.9
EW
Edwards Lifesciences Corporation
$51.70BUSDP/E 53.4
DXCM
DexCom, Inc.
$34.85BUSDP/E 36.5
GEHC
GE HealthCare Technologies Inc. Common Stock
$34.04BUSDP/E 17.2
PHIA
Koninklijke Philips N.V.
$25.08BUSDP/E 20.7
PHG
Koninklijke Philips N.V.
$26.80BUSDP/E 20.8
STE
STERIS plc
$23.20BUSDP/E 29.1
ZBH
Zimmer Biomet Holdings, Inc.
$19.26BUSDP/E 24.5
PEN
Penumbra, Inc.
$12.81BUSDP/E 79.7
SNN
Smith & Nephew plc
$12.25BUSDP/E 19.9
SN
Smith & Nephew plc
$11.48BUSDP/E 19.8
GMED
Globus Medical, Inc.
$11.67BUSDP/E 22.2
GKOS
Glaukos Corp
$10.91BUSD
EUZ
Eckert & Ziegler Strahlen-und Medizinte AG
$10.01BUSDP/E 17.1
PODD
Insulet Corporation
$10.28BUSDP/E 27.5
BIO
Bio-Rad Laboratories, Inc. Class A
$10.17BUSDP/E 46.3

Key Statistics

Company
Market Cap592.39M $
Enterprise Value515.67M $
Revenue (TTM)60.70M $
Gross Profit39.39M $
Net Income (TTM)7.63M $
Revenue/Share1.612 USD
Last Price14.74 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees129
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)64.09
P/E (Forward)30.29
PEG—
EV/EBITDA60.79
EV/Revenue8.50
P/S9.76
P/B7.21
EPS (TTM)0.23
EPS (Forward)0.49
52W Range
14.6812% of range15.16
52W High15.16 USD
52W Low14.68 USD
Profitability
Gross Margin75.42%
Oper. Margin13.98%
EBITDA Margin13.98%
Profit Margin14.62%
ROE10.42%
ROA6.76%
Growth
Revenue Growth35.40%
Earnings Growth64.60%
Cash Flow & Leverage
Operating CF18.02M $
CapEx (TTM)1.75M $
FCF Margin-10.14%
FCF Yield-1.04%
Net Debt-54.98M $
Net Debt/EBITDA-6.48
Balance Sheet
Debt/Equity0.09
Current Ratio3.59
Quick Ratio3.05
Book Value/Sh2.045 USD
Cash/Share1.604 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split2:1
Split DateMar 4, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.60 USD
Upside (mean)+26.2%
Target Range17.00 USD – 20.00 USD
$17.00+26.2% to mean$20.00
# Analysts3
Ownership
Shares Out.40.19M
Float23.20M
Insiders2.55%
Institutions32.48%
Short Interest
Short Ratio0.9d
Short % Float0.38%
Short % Out.0.29%
Shares Short116.52K
Short (prev mo.)183.71K
Technical
SMA 5015.21 (-3.1%)
SMA 20012.94 (+13.9%)
Beta0.10
S&P 52W Chg19.18%
Avg Vol (30d)47.34K
Avg Vol (10d)162.04K
Technical Indicators
RSI (14)44.7
MACD-0.0609
MACD Signal0.0609
MACD Hist.-0.1218
BB Upper16.64 USD
BB Middle15.42 USD
BB Lower14.20 USD
BB Width15.88%
ATR (14)0.8658 USD
Vol Ratio (20d)0.30x